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Abstract
Background and Objectives CHF 5993 is an extrafine
‘triple therapy’ combination of the long-acting muscarinic
antagonist glycopyrronium bromide (GB), the long-acting
b2-agonist formoterol fumarate (FF), and the inhaled cor-
ticosteroid beclometasone dipropionate (BDP). It is in
development for chronic obstructive pulmonary disease
and asthma delivered via pressurised metered-dose inhaler.
Methods This two-period, open-label, crossover study
examined the drug–drug interaction of CHF 5993 and
cimetidine. In one period, subjects received cimetidine
800 mg twice daily for 6 days; on the fourth day they also
received CHF 5993 (BDP/FF/GB 400/24/100 lg). In the
other, they received CHF 5993 alone. Primary objective
was to compare the area under the plasma concentration–
time curve from time 0 to last quantifiable concentration
(AUC0–t) of GB, with and without cimetidine. Secondary
endpoints included GB AUC0–12h, maximum concentration
(Cmax), time to Cmax (tmax), elimination half-life (t) and
urinary excretion. Pharmacokinetic parameters of BDP,
beclometasone-17-monopropionate (B17MP; active
metabolite of BDP) and formoterol were also evaluated.
Results Twenty-six subjects were randomised; 25 com-
pleted. Co-administration of CHF 5993 and cimetidine
resulted in small, statistically significant increases in GB
AUC0–t, AUC0–12h and Cmax vs CHF 5993 (ratios 1.16,
1.21 and 1.26, respectively); t, tmax and urinary excretion
were unaffected. There were small, statistically significant
increases in formoterol AUC0–t, AUC0–24h and t follow-
ing co-administration of cimetidine and CHF 5993; urinary
excretion was unaffected. There were no significant dif-
ferences for either BDP or B17MP. There were few
adverse events (AEs), and no serious AEs.
Conclusions Overall, this study indicates that there is no
clinically relevant drug–drug interaction between CHF
5993 and cimetidine.
Key Points
This study evaluated the drug–drug interaction
between CHF 5993 (a triple combination inhaler
containing glycopyrronium bromide [GB],
formoterol fumarate, and beclometasone
dipropionate) and cimetidine.
The component of CHF 5993 of particular interest in
terms of this potential interaction is GB. There were
small, although statistically significant, increases in a
number of the GB plasma pharmacokinetic
parameters as a result of cimetidine co-administration,
with total exposure increased by 16 %, and peak
concentration by 26 %.
The safety of GB has been evaluated at a dose up to
8 times the minimally effective dose in patients with
COPD, and so this study indicates that there is no
clinically relevant drug–drug interaction between
CHF 5993 and cimetidine.
ClinicalTrials.gov: NCT02287272.
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1 Introduction
One of the prescribed maintenance treatments indicated for
chronic obstructive pulmonary disease (COPD) is an
inhaled combination of a long-acting b2-agonist (LABA),
long-acting muscarinic antagonist (LAMA) and inhaled
corticosteroid (ICS) [1]. Such ‘triple therapy’ has been
shown to provide clinical benefits to patients in terms of
bronchodilation, dyspnoea, exacerbations and mortality [2–
6], yet currently to administer such a combination requires
at least two inhalers, often of different types, adding
complexity to patients’ treatment. CHF 5993 is a combi-
nation of the LAMA glycopyrronium bromide (GB), the
LABA formoterol fumarate (FF) and the ICS beclometa-
sone dipropionate (BDP), in development for the man-
agement of COPD and asthma, delivered via a pressurised
metered-dose inhaler (pMDI). The same pMDI format is
also used for a fixed combination of FF and BDP (Foster,
Chiesi Farmaceutici SpA, Parma, Italy) approved for
asthma and COPD. All three components of CHF 5993 are
formulated as extrafine particles, which support higher total
lung delivery as well as deeper and more uniform distri-
bution within the airways [7]. An early study conducted in
healthy volunteers compared the pharmacokinetics of FF/
BDP plus GB (in separate pMDIs) with CHF 5993 [8].
There were no clinically relevant differences between the
free and fixed combinations in any pharmacokinetic
parameter assessed, suggesting that there is no biophar-
maceutical interaction as a result of co-formulating the
three molecules in a single inhaler.
The potential for drug–drug interactions with CHF 5993
was investigated focusing predominantly on GB, which,
based on pharmacokinetic characteristics, is expected to be
the CHF 5993 component more susceptible to interaction
with other drugs. BDP undergoes rapid metabolism via
esterase enzymes to the active metabolite beclometasone-
17-monopropionate (B17MP) [9, 10], with both BDP and
B17MP mainly eliminated in the faeces [9]. FF is primarily
metabolised in the liver by direct glucuronidation and O-
demethylation followed by conjugation to inactive
metabolites, then urinary excretion [11–13]. O-Demethy-
lation is primarily due to cytochrome P450 (CYP)—in
particular CYP2D6 and CYP2C9 [14]. In contrast, GB is
eliminated by both hepatic and renal routes. In a series of
in vitro studies, GB was shown to be a substrate of organic
cation transporter 1 (OCT1) (Michaelis constant
[Km] = 43.6 lM), of organic cation transporter 2 (OCT2)
(Km = 14.1 lM) and of multidrug and toxin extrusion
transporter 1 (MATE1) (Km = 62.1 lM) (data on file;
Chiesi Farmaceutici SpA). OCT1 is expressed predomi-
nantly in the liver, OCT2 in the kidney, and MATE1 in
both organs. OCT1 and OCT2 are uptake transporters,
responsible for removing substrates from the blood,
whereas MATE1 is responsible for elimination of its sub-
strates into the urine or bile. Ideally, to study GB drug–
drug interactions, inhibitors of OCT1, OCT2 and MATE1
are needed. The inhibitors of OCT1 currently available
(e.g. quinine, quinidine and disopyramide [15]) are
unsuitable for use in clinical trials, as the doses required to
induce significant inhibition are toxic. Cimetidine, how-
ever, has been shown to inhibit both OCT2 and MATE1
when administered at an oral dose of 800 mg twice daily
(BID) [16, 17], which is below the maximum dose that has
been approved for the treatment of duodenal and gastric
ulcer (2.4 g daily) [18] and it is, therefore, an ideal can-
didate for studying OCT2 and MATE1-related interactions.
Cimetidine is also a typical inhibitor of cytochrome P450
(including CYP2D6 and CYP2C9) [14], and could also be
anticipated to exhibit a drug–drug interaction with FF. The
aim of this study was to examine the pharmacokinetic and
safety profile of CHF 5993 with and without cimetidine.
The evaluation was conducted in healthy volunteers, and at
steady state of cimetidine. The primary objective was to
evaluate the pharmacokinetic interaction when CHF 5993
was administered with cimetidine, by comparing the area
under the plasma concentration–time curve from time 0 to
the last quantifiable concentration (AUC0–t) of GB, after a
single dose of CHF 5993 administered alone or at steady
state of cimetidine. Secondary objectives included com-
parison of the other pharmacokinetic parameters of GB and
of the systemic exposure of BDP, B17MP and formoterol,
in terms of AUC0–t, AUC0–12h, AUC0–24h, maximum con-
centration (Cmax), time to maximum concentration (tmax),
and plasma elimination half-life (t). In addition, the uri-
nary excretion of GB and formoterol was evaluated with
respect to the amount of drug excreted into the urine in the
collection interval (Ae), the fraction excreted (fe) and
urinary clearance (CLr).
2 Subjects and Methods
2.1 Trial Design
This two-period, two-way crossover design, open-label
study started with a screening visit to assess subject eligi-
bility 3–21 days before randomisation. In one treatment
period, subjects received cimetidine ? CHF 5993
(Table 1); in the other, they received CHF 5993 alone, with
a 10- to 14-day wash-out period between CHF 5993
administrations in the two treatment periods.
The cimetidine ? CHF 5993 treatment period lasted
seven days. On Days -3 and -2, subjects received the
morning dose of cimetidine at the clinic, and were
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instructed to take the evening dose at home. From the
morning of Day -1 to the evening of Day 3, subjects
received all doses of cimetidine at the clinic, with the dose
of CHF 5993 taken on the morning of Day 1. In the CHF
5993 treatment period, the dose of CHF 5993 was taken on
the morning of Day 1. In both treatment periods, subjects
remained in the clinic from the evening of Day -1 (the
evening prior to CHF 5993 dosing) and up to Day 4, with
the final assessments on the morning of Day 4.
Blood samples for CHF 5993 evaluation were collected
pre-dose and at 5, 10, 15 and 30 min, and 1, 2, 4, 6, 8, 12,
24, 36, 48 and 72 h post-dose in each treatment period.
Samples for cimetidine evaluation were collected before
the morning administration of cimetidine from Day –2 to
Day 3, with a final sample collected on the morning of Day
4. Plasma was separated in a refrigerated centrifuge
(?4 C) at 2500g for 15 min. Urine was collected for
evaluation of GB and formoterol at pre-dose, and 0–4, 4–8,
8–12, 12–24, 24–36, 36–48, 48–60 and 60–72 h post-dose.
Plasma and urine samples were analysed in a central lab-
oratory using validated liquid chromatography [19, 20]
followed by tandem mass spectrometry detection methods.
GB concentration levels were determined in lithium-hep-
arinised plasma and in bovine serum albumin urine after
solid/liquid extraction. The GB lower limits of quantifica-
tion (LLOQs) were 5.00 and 20.0 pg/mL in plasma and
urine, respectively. Formoterol concentration levels were
determined in acidified lithium-heparinised plasma and in
urine, as free and total fractions, following a solid/liquid
extraction of the samples. The formoterol LLOQs were
2.00 and 10.0 pg/mL in plasma and urine, respectively.
Concentration levels of BDP and its metabolite B17MP
were determined in dipotassium ethylene diamine tetra-
acetic acid (K2EDTA) human plasma after liquid/liquid
extraction. The BDP and B17MP LLOQ in plasma was
20.0 pg/mL. Cimetidine was analysed in lithium-hep-
arinised plasma samples after protein precipitation extrac-
tion, with an LLOQ of 5.0 ng/mL. The detailed analytical
methods are described in the supplementary material.
Other than study medication, no drug treatment was
permitted from 14 days prior to the screening visit until
completion of the last study procedures, with the exception
of occasional paracetamol and of hormonal contraceptives
and hormone replacement treatment for post-menopausal
women. Alcohol and xanthine-containing foods or bever-
ages or grapefruit-containing foods or beverages were not
permitted from 48 h prior to each intake of CHF 5993 until
the end of the treatment period. Caffeine was limited to 5
cups or glasses per day of caffeinated beverages. Subjects
were fasted for at least 10 h prior to CHF 5993 dosing until
2 h post-dose; fluid intake was forbidden from 1 h prior to
dosing until 1 h post-dose.
The study is registered at ClinicalTrials.gov
(NCT02287272).
2.2 Participants
The study recruited healthy males and females, aged
18–45 years, and with body mass index between 18 and
30 kg/m2, inclusive. All subjects were to have serum cre-
atinine within the normal range (0.7–1.2 mg/dL) and an
estimated glomerular filtration rate[80 mL/min/1.73 m2.
Non- or ex-smokers (with a smoking history \5 pack-
years) were eligible. The main exclusion criteria were
clinically relevant laboratory values or conditions, includ-
ing abnormal electrocardiogram (ECG) or systolic or
diastolic blood pressure, and contraindication to the use of
anticholinergics, or hypersensitivity to the treatments or
excipients used during the study.
2.3 Interventions
All study medications were open label. In both treatment
periods, subjects received a single dose of four consecutive
inhalations of CHF 5993 (BDP/FF/GB 100/6/25 lg per
actuation) via pMDI, giving a total dose of 400 lg of BDP,
24 lg of FF and 100 lg of GB. The GB dose (100 lg) was
anticipated to provide measurable pharmacokinetic data
over a full 24-h period. In one of the two treatment periods,
subjects received cimetidine 800 mg (2 tablets of cime-
tidine 400 mg) BID for 6 days. Subjects were randomised
to one of two treatment sequences according to a
Table 1 Visit structure and administration scheme
Treatment period Time Days in treatment period
Days –3 and –2 Day –1 Day 1 Days 2 and 3 Day 4
Cimetidine ? CHF 5993 Morning Cimetidine Cimetidine Cimetidine ? CHF 5993 Cimetidine
Evening Cimetidinea Cimetidine Cimetidine Cimetidine
CHF 5993 Morning CHF 5993
Evening
a Taken at home
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randomisation list that was generated by the Statistics and
Data Management Department of Chiesi Farmaceutici SpA
(the study sponsor) using a validated computerised system.
2.4 Statistical Methods
The pharmacokinetic analysis was performed using Phoe-
nix 6.2 or later (Pharsight Corporation, Palo Alto, CA,
USA). Standard non-compartmental methods were used for
the calculation of the plasma parameters from the indi-
vidual plasma drug concentrations versus time profile (see
supplementary material).
The primary endpoint, plasma GB AUC0–t, was log
transformed and analysed using a linear model including
treatment, sequence, period and subject within sequence as
fixed effects. The ratios of adjusted geometric means
between CHF 5993 ? cimetidine and CHF 5993 alone
were calculated with their 90 % two-sided confidence
intervals (CIs). Most of the secondary plasma pharma-
cokinetic objectives were also log transformed and anal-
ysed using this linear model. The exception was tmax, for
which the Hodges–Lehmann non-parametric estimate of
location shift between treatments (based on untransformed
data) is provided with its 90 % two-sided CI. Urinary
excretion was summarised by treatment using descriptive
statistics.
It was planned for all pharmacokinetic values below the
lower limit of quantification (LLOQ; 5 pg/mL) to be set to
0. However, since GB concentrations were below the
LLOQ starting from 4 h post-dose and samples were col-
lected over 72 h post-dose, a large portion of the GB
plasma concentration vs time curve could not be accurately
assessed in a number of subjects. A post hoc analysis was
therefore conducted, setting post-dose values below the
LLOQ to LLOQ/2, to provide an ‘average’ estimate of the
actual concentration fluctuating between the LLOQ and
zero and, consequently, to better estimate GB pharma-
cokinetic parameters. This approach was used for all GB
parameters reported here, except t (the flat elimination
phase due to all data being set to LLOQ/2 did not allow the
estimation of t using this method, so the original
methodology was used).
Compliance with cimetidine was calculated on the basis
of the used/unused drug returned by each subject, as the
percentage of scheduled doses actually taken. As CHF
5993 was only administered in study centres, compliance
was evaluated on the basis of the number of correct
inhalations recorded in the electronic Case Report Form.
Pharmacokinetic variables were analysed on the phar-
macokinetic population, which was all subjects from the
safety population excluding subjects without any valid
pharmacokinetic measurement or with major protocol
deviations significantly affecting pharmacokinetics.
2.5 Safety and Tolerability
The safety and tolerability of study treatment was evalu-
ated by recording adverse events (AEs) and serious adverse
events (SAEs) were recorded. The number of subjects who
experienced at least one treatment-emergent AE (TEAE),
treatment-related AE, serious TEAE, seriousness-related
TEAE, or TEAE leading to study drug discontinuation or
death were summarised by treatment.
Adverse events were captured from the time that a
subject signed informed consent until their participation in
the study ended. An AE was defined as ‘any untoward
medical occurrence in a patient or clinical trial subject
administered a medicinal product and which does not
necessarily have a causal relationship with this treatment’.
An SAE was defined as an event that resulted in death, or
persistent or significant disability or incapacity, was life-
threatening, required (or prolonged) hospitalisation, was a
congenital abnormality or birth defect, or was medically
significant. AEs were rated by the reporting investigator on
a three-point scale:
• Mild: the event causes a minor discomfort, or does not
interfere with daily activity of the subject, or does not
lead to either modification of test treatment dosage or
establishment of a correcting treatment.
• Moderate: the event perturbs the usual activity of the
subject and is of a sufficient severity to make the
subject uncomfortable. The event leads to a diminution
of dosage of the test treatment, or a temporary
interruption of its administration or to the establishment
of a correcting treatment.
• Severe: the event prevents any usual routine activity of
the subject and causes severe discomfort. It may be of
such severity to cause the definitive interruption of test
treatment.
All safety variables were analysed on the safety popu-
lation, which comprised all randomised subjects who
received at least one dose of study treatment.
2.6 Sample Size
The sample size calculation was not based on the power to
investigate a formal hypothesis, but was conducted to
evaluate the precision of the estimate of the adjusted means
ratio for GB AUC0–t. Estimating a within-subject coeffi-
cient of variation of 32.9 %, a total sample size of 22
evaluable subjects (11 per sequence) would ensure that the
lower and upper limit of the 90 % CI for the ratio of the
adjusted means corresponded approximately to the 85 and
118 % of the point estimate of the ratio. Considering a
screening failure rate of approximately 50 % and a non-
evaluable rate of approximately 10 %, a total of about 52
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In total, 43 subjects were screened (Fig. 1). Seventeen
subjects were not randomised (11 subjects were not eligible
to enter the study, 3 withdrew consent and 3 were back-
ups). The other 26 subjects were randomised (54 % female,
mean age 33.1 years, 84.6 % non-smokers; Table 2), one
subsequently withdrawing consent before receiving CHF
5993 but after having received cimetidine for 3 days. The
remaining 25 subjects completed the study, and compliance
with both cimetidine and CHF 5993 was 100 %.
3.2 Outcomes
3.2.1 GB Pharmacokinetics
The co-administration of CHF 5993 and cimetidine resul-
ted in small but statistically significant increases in
AUC0–t, AUC0–12h and Cmax compared with CHF 5993
alone, since the lower limit of the 90 % CI of the ratio
exceeded 1.0, whereas t was unchanged (Table 3). Mean
plasma GB levels reached a peak by the first post-dose
sampling time point (5 min), and then declined rapidly
(Fig. 2). At 4 h post-dose, GB plasma concentration values
were below the LLOQ for one subject following adminis-
tration of cimetidine ? CHF 5993 and three subjects fol-
lowing administration of CHF 5993. By 8 h post-dose
mean GB levels for both treatments were below the LLOQ
in most subjects. Overall urinary excretion of GB was
unaffected by the co-administration of cimetidine (Fig. 3).
Approximately, half of the total excretion occurred in the
first 12 h (44 and 47 % for cimetidine ? CHF 5993 and
CHF 5993, respectively). CLr of total GB was significantly
lower for cimetidine ? CHF 5993 compared with CHF
5993 (Table 3). In a post hoc analysis, unbound GB CLr
was 491 and 547 mL/min for cimetidine ? CHF 5993 and
CHF 5993 alone, respectively.
3.2.2 Formoterol, B17MP and BDP Pharmacokinetics
There were small but statistically significant increases in
formoterol AUC0–t, AUC0–24h and t following co-admin-
istration of cimetidine ? CHF 5993 compared with CHF
5993 alone, but no significant change in Cmax (Table 4).
Urinary excretion of formoterol was unaffected by co-ad-
ministration of cimetidine, with more than half of the total
excretion occurring in the first 4 h post-dose (Fig. 4). For-
moterol CLr was significantly lower following co-adminis-
tration of cimetidine ? CHF 5993 than following CHF 5993
alone (mean ± SD 231 ± 78.5 and 313 ± 98.2 mL/min
respectively; ratio 0.75, 90 % CI 0.65, 0.85). There were no
statistically significant differences in any of the plasma
pharmacokinetic parameters for either BDP or B17MP.
3.2.3 Cimetidine Pharmacokinetics
Mean pre-dose cimetidine plasma concentrations were
312.7, 361.8, 270.2, 331.7, 308.9 and 312.7 ng/mL fromFig. 1 Subject flow through the study










Mean (SD) 33.1 (8.2)
Range 21–45
Body mass index, kg/m2
Mean (SD) 24.1 (3.4)
Range 17.4–29.4




Glomerular filtration rate, mean (SD), mL/min/
1.73 m2
95.3 (12.7)
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the morning of Day –2 to Day 4, indicating that cimetidine
was at steady state throughout the assessment of CHF 5993
pharmacokinetic values.
3.3 Safety and Tolerability
The number and percentage of subjects reporting TEAEs
are shown in Table 5. The number of events occurring
during exposure to cimetidine ? CHF 5993 was more than
double the number of events occurring during CHF 5993
alone. However, the number of subjects experiencing at
least one TEAE was comparable between the two periods.
Moreover, no serious TEAEs were reported.
In terms of relationship to dosing of the TEAEs occur-
ring in at least two subjects, 5 of the events with cime-
tidine ? CHF 5993 started on the day that CHF 5993 was
administered (abdominal pain, dizziness and three
Table 3 GB pharmacokinetic
parameters (pharmacokinetic
population)
Parameter Cimetidine ? CHF 5993 (N = 25) CHF 5993 (N = 25) Ratiog (90 % CI)
Plasma
AUC0–t (pgh/mL) 330 ± 138a 272 ± 70.6 1.16 (1.07, 1.27)
AUC0–12h (pgh/mL) 138 ± 69.6a 111 ± 51.0 1.21 (1.08, 1.36)
Cmax (pg/mL) 63.3 ± 57.0 47.8 ± 40.6 1.26 (1.00, 1.58)
tmax (h) 0.08 (0.08; 4.02) 0.08 (0.05; 2.00) 0.00 (0.00, 0.42)
t (h) 2.86 ± 0.71
b 3.73 ± 1.78c 1.02 (0.78, 1.35)
Urine
fe (%) 5.83 ± 3.34d 5.36 ± 2.34e Not evaluated
CLr (mL/min) 296 ± 196f 330 ± 127e 0.80 (0.71, 0.90)
Data are mean ± standard deviation, except tmax which is median (range)
CI confidence interval, AUC0–t area under the plasma concentration–time curve from time 0 to the last
quantifiable concentration, AUC0–12h area under the plasma concentration–time curve from time 0 to 12 h
post-dose, Cmax maximum concentration, tmax time to maximum concentration, t plasma elimination half-
life, fe fraction excreted, CLr urinary clearance, GB glycopyrronium bromide
a N = 24
b N = 8
c N = 13
d N = 23
e N = 21
f N = 22
g Ratio of adjusted geometric means, except tmax (see Sect. 2.4)
Fig. 2 Mean GB plasma concentration vs time profiles, up to 8 h
post-dose (main figure) and up to 2 h post-dose (inset figure)
(pharmacokinetic population). GB glycopyrronium bromide
Fig. 3 Mean GB urinary excretion (pharmacokinetic population). Ae
mean ± standard deviation amount excreted, GB glycopyrronium
bromide
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occurrences of headache), compared with 6 of the events
with CHF 5993 alone (two each of abdominal discomfort,
headache and vomiting). The other TEAEs in Table 5 were
started on days when CHF 5993 was not administered.
4 Discussion
This study evaluated the extent of the drug–drug interac-
tion between CHF 5993 and the OCT2/MATE1 inhibitor
cimetidine. The component of CHF 5993 of particular
interest in terms of this potential interaction is GB, since
due to its pharmacokinetic profile, it is more susceptible to
interaction with inhibitors of OCT1, OCT2 and MATE1
that are involved in GB renal and hepatic elimination.
There were small, although statistically significant,
increases in a number of the GB plasma pharmacokinetic
parameters as a result of cimetidine co-administration, with
total exposure increased by 16 %, and peak concentration
by 26 %. GB was rapidly absorbed, reaching peak plasma
concentration within 5 min (with or without cimetidine co-
administration). GB was then rapidly eliminated, with the
mean concentration below the LLOQ by 8 h post-dose.
Urinary excretion was similarly rapid, with nearly 50 %
occurring in the first 12 h. The CLr of unbound GB was
491 and 547 mL/min for cimetidine ? CHF 5993 and CHF
5993 alone, respectively; given the mean glomerular fil-
tration rate was 95.3 mL/min/1.73 m2, this suggests that
active transport was involved in the excretion of GB. Since
drug-related safety would be anticipated to correlate with
systemic exposure, the rapid excretion of GB and the rel-
atively small increases in pharmacokinetic parameters
resulting from cimetidine co-administration are reassur-
ing—especially since the GB dose used in this study (a
single dose of 100 lg) is four times the dose that in another
study was minimally effective in patients with COPD
(25 lg BID) [21], and with no safety signal observed with
single doses as high as 200 lg [22]. These findings are
further supported by the results from a previous 14-day
study in which BDP/FF was administered in one inhaler
and GB in a second to patients with COPD, the main aim of
which was an investigation of cardiac safety (data on file).
In this earlier study, GB 25 and 50 lg BID added to BDP/
FF overall was not associated with an increased risk of an
elevated heart rate (measured by means of 24-h digital
Holter ECG) compared with BDP/FF alone, suggesting that
an increase in GB exposure of 16 % is unlikely to result in
cardiovascular safety concerns.
These results are broadly consistent with a pharma-
cokinetic analysis of a standard particle formulation of
glycopyrronium that has been approved for once-daily
dosing (at a dose of 50 lg daily), in which glycopyrronium
plasma concentration also reached a peak rapidly (by 5 min
Fig. 4 Mean formoterol urinary excretion (pharmacokinetic popula-
tion). Ae mean ± standard deviation amount excreted
Table 5 Overall and most frequent (in C2 subjects) treatment-emergent adverse events (safety population)
Parameter Cimetidine ? CHF 5993 (N = 25) CHF 5993 (N = 25) All treatments (N = 25)
n (%) Events n (%) Events n (%) Events
At least one TEAE 8 (32.0) 20 7 (28.0) 9 12 (48.0) 29
Treatment-related AE 2 (8.0) 2 1 (4.0) 1 3 (12.0) 3
Most frequently reported TEAEs (in C2 subjects during any treatment)
Headache 4 (16.0) 4 3 (12.0) 3 6 (24.0) 7
Dizziness 4 (16.0) 4 0 0 4 (16.0) 4
Abdominal pain 3 (12.0) 3 0 0 3 (12.0) 3
Abdominal discomfort 0 0 2 (8.0) 2 2 (8.0) 2
Vomiting 0 0 2 (8.0) 2 2 (8.0) 2
N number of subjects in the safety population, n number of subjects with event, TEAE treatment-emergent adverse event
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post-dose), and then rapidly declined [23]. Although it is
difficult to compare these two studies directly, mean sys-
temic exposure (AUC0–t) was lower for the extrafine par-
ticle formulation tested in the current study (330 and
272 pgh/mL with and without cimetidine, respectively)
than for the standard particle formulation (919 and
771 pgh/mL, respectively).
A high degree of variability of GB Cmax was observed in
this study, with standard deviations similar in size to the
mean. Given most of the cimetidine doses (and all of the
CHF 5993 doses) were administered at the clinic, this
cannot be explained by compliance issues, and since all
patients were trained on device use (with all inhalations
observed), this is unlikely to be inhaler technique. The
most logical explanation for this variability is the rapid
metabolism and plasma elimination of GB. As can be seen
from Fig. 3 and Table 3, the observed mean maximum
plasma concentration was at the first sampling timepoint,
with the concentration then rapidly decreasing. This plasma
concentration–time profile makes it very difficult to capture
the actual maximum plasma concentration for an individual
patient. In contrast, the variability of the AUC parameters
is much smaller, since these parameters are largely driven
by samples taken at timepoints when the curve is flatter
(and, therefore, individual patient variability has less
impact on the results). This means that the two AUC
parameters are more informative than Cmax in terms of the
effect of cimetidine on the pharmacokinetics of GB.
The apparent IC50 values for cimetidine inhibition of
OCT2 and MATE1 are 23 and 5.7 lM, respectively [17].
Since the steady-state Cmax of cimetidine after 800 mg BID
is estimated to be approximately 19 lM (extrapolated from
data reported for cimetidine 400 mg BID [24]), the cime-
tidine dose used in the current study (800 mg BID) is
anticipated to result in plasma levels able to provide sig-
nificant interaction with OCT2 and MATE1. Although
there is some uncertainty over the extent of transporter
inhibition that this cimetidine dose would induce, previous
in vivo studies have demonstrated transporter inhibition at
doses of 400 or 800 mg BID [25, 26]. Some in vitro studies
suggest that cimetidine is only a weak inhibitor of CYP2D6
[27] and CYP2C9 [28, 29]. However, other in vivo studies
have shown that cimetidine decreased the systemic and
metabolic clearance of tolbutamide (dependent on
CYP2C9 activity) by approximately 40 % at a dose of
1.6 g/day [30], of desipramine (dependent on CYP2D6
activity) by approximately 47 % at a dose of 1.2 g/day
[31], and of propranolol (CYP2D6 substrate) after a dose of
1 g/day [32]. Furthermore, in our study we observed sta-
tistically significant increases in formoterol systemic
exposure that were consistent with the effects of cimetidine
on cytochrome P450. Taken together, this evidence sug-
gests that the cimetidine dose administered in our study
was sufficient in terms of effect on metabolism and
transporters.
As would be anticipated from the metabolism and
excretion profiles, the plasma pharmacokinetic profiles for
BDP and B17MP were not significantly impacted by co-
administration of cimetidine. There were small but signif-
icant increases in formoterol systemic exposure (although
not maximum concentration), consistent with the effect of
cimetidine on cytochrome P450. However, in a 12-week
study of a standard particle formulation of FF that com-
pared FF 12 lg BID with FF 24 lg BID, ipratropium
40 lg four times a day and placebo, the 24 lg BID dose of
FF was associated with a similar rate of AEs [33]. Whilst
care should be taken comparing one formulation with
another, this previous 12-week study does suggest that the
21 % increase in systemic exposure observed in the current
study is unlikely to result in safety concerns.
Although the current study cannot provide definitive
data on the safety of CHF 5993, it is reassuring that few
subjects experienced a treatment-related TEAE, and by
comparing the treatments it would appear that cimetidine
was responsible for most of the events—especially since
headache and dizziness are common adverse reactions
reported with cimetidine [18]. It is also notable that in
longer term studies in patients with COPD, inhaled GB (in
a different formulation) has demonstrated an overall
favourable safety profile [34–36].
5 Conclusions
Overall, this study indicates that there is no clinically rel-
evant drug–drug interaction between GB and the other
components of the triple combination of GB/FF/BDP that
comprise extrafine CHF 5993, and cimetidine, a potent
inhibitor of organic cation transport. This reduces the
likelihood of relevant interactions with other medications
involved in the OCT2 and MATE1 pathways and poten-
tially co-administered with CHF 5993. The study findings
also support a favourable overall safety and tolerability
profile for CHF 5993 when delivered in this setting.
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